Traders sold shares of Nektar Therapeutics (NASDAQ:NKTR) on strength during trading on Wednesday. $117.17 million flowed into the stock on the tick-up and $133.71 million flowed out of the stock on the tick-down, for a money net flow of $16.54 million out of the stock. Of all companies tracked, Nektar Therapeutics had the 33rd highest net out-flow for the day. Nektar Therapeutics traded up $0.87 for the day and closed at $68.90
Several brokerages have recently weighed in on NKTR. Canaccord Genuity Group increased their target price on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Cowen began coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 7th. They set an “outperform” rating for the company. Canaccord Genuity began coverage on shares of Nektar Therapeutics in a research note on Thursday, November 9th. They set a “buy” rating and a $35.00 target price for the company. Roth Capital set a $45.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, Zacks Investment Research downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. Nektar Therapeutics has a consensus rating of “Buy” and an average target price of $38.08.
The stock has a market cap of $11,340.00, a price-to-earnings ratio of -101.41 and a beta of 1.81. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.16. The firm had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a net margin of 39.80% and a return on equity of 557.76%. The firm’s revenue for the quarter was up 321.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.32) earnings per share. equities research analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current fiscal year.
In related news, Director Christopher A. Kuebler sold 30,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now directly owns 70,500 shares of the company’s stock, valued at $4,135,530. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Howard W. Robin sold 83,334 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the transaction, the chief executive officer now directly owns 235,838 shares of the company’s stock, valued at $5,558,701.66. The disclosure for this sale can be found here. Insiders have sold 614,017 shares of company stock valued at $20,587,527 over the last three months. 5.44% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of NKTR. Janus Henderson Group PLC purchased a new position in Nektar Therapeutics in the second quarter valued at about $34,661,000. PointState Capital LP increased its holdings in Nektar Therapeutics by 281.7% in the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock valued at $33,841,000 after buying an additional 1,277,500 shares in the last quarter. Rubric Capital Management LP purchased a new position in Nektar Therapeutics in the third quarter valued at about $23,924,000. State Street Corp increased its holdings in Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after buying an additional 447,023 shares in the last quarter. Finally, Numeric Investors LLC increased its holdings in Nektar Therapeutics by 2,111.5% in the second quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock valued at $8,616,000 after buying an additional 420,800 shares in the last quarter. 96.01% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Investors Sell Nektar Therapeutics (NKTR) on Strength (NKTR)” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2018/01/13/investors-sell-nektar-therapeutics-nktr-on-strength-nktr.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.